3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
6
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immune System Diseases
2
Gastro-enteropancreatic neuroendocrine tumor
2
AIDS-Related Complex
2
Urogenital Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Recurrence
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Pheochromocytoma
1
Paraganglioma
1
Neuroendocrine Tumors
1
Metastatic Neuroendocrine Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Interventions
enzalutamide
7
Prednisone
7
cabazitaxel
6
Radiosurgery
6
Docetaxel
5
Androgen Antagonists
4
Abiraterone Acetate
4
XRP6258
2
Standard of Care
2
talazoparib
1
sipuleucel-T
1
rucaparib
1
pembrolizumab
1
olaparib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
darolutamide
1
apalutamide
1
Zuclomiphene
1
Radiotherapy, Image-Guided
1
Radiotherapy
1
Prednisolone
1
Positron Emission Tomography Computed Tomography
1
Pluvicto
1
Midazolam
1
Lutetium-177
1
Lutetium
1
Lenograstim
1
LY3023414
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Prostate Cancer Metastatic
×
Lutetium
×
Clear all
NCT06320067
2025-09-26
STAMPEDE2
University College, London
Phase 3
Recruiting
3,360 enrolled